KCM
KRYS icon

Kennedy Capital Management’s Krystal Biotech KRYS Stock Holding History

Kennedy Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.36M Buy
9,034
+4,130
+84% +$1.23M 0.06% 382
2026
Q1 		$1.27M Buy
4,904
+403
+9% +$107K 0.03% 462
2025
Q4 		$1.11M Sell
4,501
-34,790
-89% -$7.32M 0.02% 476
2025
Q3 		$6.94M Buy
39,291
+1,145
+3% +$171K 0.15% 233
2025
Q2 		$5.24M Sell
38,146
-3,372
-8% -$495K 0.13% 283
2025
Q1 		$7.49M Buy
41,518
+13,807
+50% +$2.32M 0.18% 198
2024
Q4 		$4.34M Buy
27,711
+22,517
+434% +$3.99M 0.1% 351
2024
Q3 		$945K Buy
5,194
+237
+5% +$45.7K 0.02% 595
2024
Q2 		$910K Buy
4,957
+2,056
+71% +$345K 0.02% 599
2024
Q1 		$516K Sell
2,901
-26,772
-90% -$3.72M 0.01% 656
2023
Q4 		$3.68M Buy
+29,673
New +$3.29M 0.08% 365
2023
Q2 		– Sell
-25,807
Closed -$2.07M – 681
2023
Q1 		$2.07M Sell
25,807
-13
-0.1% -$1.02K 0.06% 396
2022
Q4 		$2.05M Sell
25,820
-1,465
-5% -$109K 0.06% 411
2022
Q3 		$1.9M Buy
+27,285
New +$1.97M 0.06% 423

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Kennedy Capital Management's KRYS Position: Q2 2026 in Review

Kennedy Capital Management increased its Krystal Biotech (KRYS) stake by 84% in Q2 2026, buying an estimated $1.23M and bringing the position to 9,034 shares worth $3.36M. The position accounts for 0.06% of the portfolio, ranked #382.

Kennedy Capital Management first reported a position in KRYS in Q3 2022 and has held it in 14 quarters since. The position peaked at $7.49M in Q1 2025. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Kennedy Capital Management held 9,034 shares of Krystal Biotech worth $3.36M as of Q2 2026.
  • Kennedy Capital Management bought 4,130 Krystal Biotech shares in Q2 2026, an estimated $1.23M.
  • Krystal Biotech made up 0.06% of Kennedy Capital Management's portfolio in Q2 2026, its #382 holding.
  • Kennedy Capital Management first reported a position in Krystal Biotech in Q3 2022 and has held it in 14 quarters since.
  • Kennedy Capital Management's Krystal Biotech position peaked at $7.49M in Q1 2025.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.